I’m on the hunt for the best stocks on the market! I think I may have just found them

This Fool is on the lookout for the best the stock market has to offer. He reckons these two could be solid candidates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investing in the stock market can be difficult. Nowadays, there’s so much information available to investors promoting things such as get-rich-quick schemes.

I’m blocking all that out. I invest in the market to build my wealth over time. I want top-quality businesses in my portfolio that I believe can perform strongly over a long stretch.

The stock market is vast, but I’ve put most of my energy into focusing on FTSE shares, which have gone on a tear this year. I like what I see with these two.

GSK

First is pharmaceutical giant GSK (LSE: GSK). The stock has taken full advantage of the market rally. It’s up 11.6% so far this year.

But with its share price sliding around 5% in the last week, I reckon now could be a time to swoop in and buy some shares. It trades on 15.1 times earnings. I see that as good value for a high-quality business.

GSK is on my list due to its defensive nature. Regardless of external issues such as a weak economy, people will always need access to medicine and treatments.

That’s not to say the stock is risk-free. For example, some market spectators have concerns about the firm’s drug pipeline. The company has underperformed compared to its peers recently. Furthermore, it’s facing further legal trouble surrounding heartburn drug Zantac, which sparked its fall recently.

But with it now having nearly 90 products in its R&D pipeline, it seems the firm is turning a corner. As such, analysts have its earnings growth rising from 3% this year to 10% and 11% in 2025 and 2026 respectively. Its 12-month price target is £19.51, which represents an 18.1% premium from its current price.

I like to target income. Therefore, its 3.6% yield, in line with the Footsie average, is also attractive.

Diageo

I also think one of the market’s best offerings right now is Diageo (LSE: DGE). Unlike GSK, its share price has faltered lately. It’s down 5.8% year to date. Diageo shares have lost 20.7% of their value in the last 12 months.

The spirit maker has struggled as consumers have cut back on splashing out on its premium brands in favour of cheaper alternatives given the current economic environment. Sales have been hit especially hard in the US, which is the company’s largest market.

But I still see an incredibly strong underlying business. The company owns high-quality names such as Guinness and Captain Morgan. In the years to come, I think demand for its products will steadily grow due to rising wealth in developing countries.

With its share price struggling, investors can now pick up Diageo shares trading on 19.2 times earnings. That’s above the Footsie average (11) but considerably lower than its historical average of around 24.

To go with that, the stock has a 3.1% yield. That may not seem enticing given some of the higher yields available on the Footsie. However, it has increased its payout for 37 years on the trot, which is an incredible record.

Charlie Keough has no position in any of the shares mentioned. The Motley Fool UK has recommended Diageo Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the S&P 500 crash in 2026?

The S&P 500 delivered impressive gains in 2025, but valuations are now running high. Are US stocks stretched to breaking…

Read more »

Teenage boy is walking back from the shop with his grandparent. He is carrying the shopping bag and they are linking arms.
Investing Articles

How much do you need in a SIPP to generate a brilliant second income of £2,000 a month?

Harvey Jones crunches the numbers to show how investors can generate a high and rising passive income from a portfolio…

Read more »

Investing Articles

Will Lloyds shares rise 76% again in 2026?

What needs to go right for Lloyds shares to post another 76% rise? Our Foolish author dives into what might…

Read more »

Investing Articles

How much passive income will I get from investing £10,000 in an ISA for 10 years?

Harvey Jones shows how he plans to boost the amount of passive income he gets when he retires, from FTSE…

Read more »

Investing Articles

Down 34% in 2025 — but could this be one of the UK’s top growth stocks for 2026?

With clarity over research funding on the horizon, could Judges Scientific be one of the UK’s best growth stocks to…

Read more »

piggy bank, searching with binoculars
Investing Articles

Can the rampant Barclays share price beat Lloyds in 2026?

Harvey Jones says the Barclays share price was neck and neck with Lloyds over the last year, and checks out…

Read more »

Investing Articles

Here’s how Rolls-Royce shares could hit £25 in 2026

If Rolls-Royce shares continue their recent performance, then £25 might be on the cards for 2026. Let's take a look…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

Prediction: in 2026 the red-hot Rolls-Royce share price could turn £10,000 into…

Harvey Jones can't believe how rapidlly the Rolls-Royce share price has climbed. Now he looks at the FTSE 100 growth…

Read more »